Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Scyx save search
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
Published: 2022-10-24 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.0%
H: 0.76%
C: -7.11%
ongoing infections positive study fungal infection
SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
Published: 2022-10-11 (Crawled : 13:20) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -0.39%
H: 12.4%
C: 4.26%
positive study
SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting
Published: 2022-09-08 (Crawled : 13:20) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.0%
H: 4.93%
C: 2.88%
ongoing research education meeting infections positive study group
SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 1.58%
H: 12.84%
C: 7.0%
meeting infections positive study
SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections
Published: 2022-07-19 (Crawled : 13:20) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 4.83%
H: 4.15%
C: -2.3%
women infections positive
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Published: 2022-05-10 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -7.98%
H: 3.06%
C: 1.02%
ongoing positive phase 3
SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections
Published: 2022-04-22 (Crawled : 16:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -18.99%
H: 2.73%
C: -8.98%
infections positive phase 3 fungal infection
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections
Published: 2022-02-10 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -3.54%
H: 7.45%
C: 4.29%
positive results positive infection phase 3 infections
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
Published: 2022-02-10 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -3.54%
H: 7.45%
C: 4.29%
approval positive results potential positive infection phase 3 submission infections
SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections
Published: 2021-04-30 (Crawled : 12:15) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.95%
H: 3.5%
C: 1.89%
positive injection infections
SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Published: 2021-03-02 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.12%
H: 8.25%
C: 6.43%
positive results ongoing fungal infections positive results phase 3 injection infections fungal infection
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.